Talking Oncology

Dr Joseph Ischia

A podcast for uro-oncologists developing a deeper understanding of the literature to ensure we apply the right evidence to the right patient.

Episodes

  1. 09/14/2021

    How to decide on the best treatment option for metastatic hormone-sensitive prostate cancer

    A/Prof Andrew Weickhardt and Dr Ainsley Campbell discuss treatment options for newly diagnosed metastatic prostate cancer, with esteemed guest Professor Ian Davis. Andrew Weickhardt is a consultant medical oncologist with a major interest in genitourinary cancers. Andrew has a joint appointment between Austin Hospital and the Olivia Newton John Cancer Research Institute. He oversees the genitourinary clinical trials program at the Austin Hospital. He has published over 20 peer reviewed publications and his research on targeted therapies has been recognised with multiple awards including two American Society for Clinical Oncology Merit Awards. Ainsley Campbell is a medical oncologist and Director of Genetics at Austin Health based in Heidelberg, Victoria. Ainsley has an interest in GU oncology and cancer genetics. Professor Ian Davis is a medical oncologist and is Professor of Medicine and Head of the Eastern Health Clinical School, Monash University & Eastern Health, in Melbourne Australia. He is an NHMRC Practitioner Fellow. He holds honorary appointments with the Olivia Newton-John Cancer Research Institute (formerly Ludwig Institute for Cancer Research) and Austin Health, is an Associate Professor of the University of Melbourne, and Associate of the University of Sydney. His primary clinical interests are in urologic cancer and melanoma, and his primary research interests are in cancer immunology and the biology of urologic cancers.

    How to decide on the best treatment option for metastatic hormone-sensitive prostate cancer
  2. 03/14/2021

    Even when it has metastasized - Radiation to the prostate in metastatic prostate cancer

    Join Joseph Ischia, Amy Teh and Nick James as they discuss radiation to the prostate in metastatic prostate cancer. Dr Amy Teh is the Lead Regional Radiation Oncologist at the ICON Cancer Centre for NSW/ACT, a consultant Radiation Oncologist at the Sydney Adventist Hospital and a Clinical Senior Lecturer at the Sydney Medical School, The University of Sydney. A member of TROG and ANZUP Clinical Trials Group, Dr Teh is lead site-investigator for the RAVES, ENZARAD, DASL-HiCap prostate cancer trials at the Sydney Adventist Hospital and has led the Prostate Brachytherapy Program at the Sydney Adventist Hospital, and also the Radiation Oncology Research Committee Co-Chair for the ICON Cancer Centre. Professor James is Consultant in Clinical Oncology at the Queen Elizabeth Hospital Birmingham and Professor of Clinical Oncology at the University of Birmingham. Professor James is internationally renowned for his work in Urological Cancer, particularly on the ground-breaking STAMPEDE trial, which has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 10,000 men. He is a regular educational speaker at conferences worldwide, recently including the American Society of Clinical Oncology, European Society of Medical Oncology and European Association of Urologists Annual Meetings. Results from STAMPEDE with both first line docetaxel chemotherapy and abiraterone have shown that big survival gains can be made by using existing treatments in novel settings. These findings have been practice changing worldwide.

    Even when it has metastasized - Radiation to the prostate in metastatic prostate cancer

About

A podcast for uro-oncologists developing a deeper understanding of the literature to ensure we apply the right evidence to the right patient.